Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 19/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 13/20 | 0.51 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | DRD3 | P35462 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25666134 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL25666155 | 0.87 | ADRB2 (0.47) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL2568651 | 0.87 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL99134 | 0.87 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL30490482 | 0.87 | ADRB2 (0.46) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL13697685 | 0.81 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL18601883 | 0.81 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL11912037 | 0.80 | ADRB2 (0.71) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL10494340 | 0.80 | ADRB2 (0.71) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL10494435 | 0.80 | ADRB2 (0.71) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9072734-B2 | Quaternary ammonium salt compounds | TEIJIN PHARMA LIMITED (JP) | 2015-07-07 | — | — | US | disclosed |
| EP-2426121-A1 | QUATERNARY AMMONIUM SALT COMPOUND | Teijin Pharma Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | TEIJIN PHARMA LIMITED (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046467-A1 | QUATERNARY AMMONIUM SALT COMPOUNDS | ADRB2, AGTR2, ADRB3 | ADRB2 1/4885ADRB1 4/4885DRD2 344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.